Needham & Company LLC cut shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from a buy rating to a hold rating in a research note released on Friday, Marketbeat.com reports. They currently have $55.00 target price on the stock.
A number of other analysts have also issued reports on PCRX. Wedbush reiterated an outperform rating and issued a $87.00 price target on shares of Pacira Pharmaceuticals in a report on Wednesday, October 25th. Janney Montgomery Scott lowered Pacira Pharmaceuticals from a neutral rating to a sell rating and set a $27.00 price target for the company. in a report on Thursday, October 26th. Piper Jaffray Companies reiterated a buy rating and issued a $55.00 price target on shares of Pacira Pharmaceuticals in a report on Friday, October 27th. Canaccord Genuity lowered Pacira Pharmaceuticals from a buy rating to a hold rating and lowered their target price for the stock from $44.00 to $33.00 in a report on Monday, October 30th. Finally, BMO Capital Markets upped their target price on Pacira Pharmaceuticals from $38.00 to $39.00 and gave the stock a market perform rating in a report on Wednesday, November 8th. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. Pacira Pharmaceuticals has an average rating of Hold and an average price target of $46.53.
Shares of Pacira Pharmaceuticals (NASDAQ PCRX) opened at $30.15 on Friday. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $1,220.00, a P/E ratio of -23.02 and a beta of 1.88. Pacira Pharmaceuticals has a twelve month low of $29.35 and a twelve month high of $58.95.
Several hedge funds have recently modified their holdings of PCRX. Millennium Management LLC acquired a new position in shares of Pacira Pharmaceuticals during the fourth quarter worth $24,644,000. Mesirow Financial Investment Management Equity Management acquired a new position in shares of Pacira Pharmaceuticals during the third quarter worth $14,671,000. Stonepine Capital Management LLC acquired a new position in shares of Pacira Pharmaceuticals during the third quarter worth $14,089,000. Epoch Investment Partners Inc. increased its position in shares of Pacira Pharmaceuticals by 195.7% during the third quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after purchasing an additional 354,728 shares in the last quarter. Finally, Consonance Capital Management LP increased its position in shares of Pacira Pharmaceuticals by 16.1% during the fourth quarter. Consonance Capital Management LP now owns 1,602,334 shares of the company’s stock worth $73,147,000 after purchasing an additional 222,200 shares in the last quarter.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.